# Claims

> Grounding: abstract-only. Claims are limited to statements directly present in `metadata.md` / `metadata.json`. The abstract gives no exact diagnostic-performance numbers, so claims remain qualitative. Numeric metadata in C04 is bibliographic metadata, not experimental evidence.

## C01: Deep learning architectures can analyze multimodal neuroimaging for Alzheimer's disease diagnosis
- **Statement**: Convolutional neural networks, recurrent neural networks, and transformer-based models have shown potential for analyzing multimodal neuroimaging data by processing structural and functional imaging modalities and extracting patterns associated with Alzheimer's pathology.
- **Status**: supported
- **Falsification criteria**: A systematic assessment of the reviewed literature finding that these architecture families cannot process structural and functional imaging modalities or do not extract Alzheimer's-associated patterns.
- **Proof**: [E01, E02]
- **Evidence basis**: The abstract's Results section directly names CNNs, RNNs, and transformer-based models and states that these models can process structural and functional imaging modalities and extract relevant features and patterns.
- **Interpretation**: This supports the review's broad framing that deep learning is useful for multimodal AD neuroimaging, but the provided input does not specify which model, dataset, or metric establishes the result.
- **Sources**:
  - architecture families and imaging-processing capability ← metadata.md (Abstract, Results) «Deep learning architectures, including convolutional neural networks, recurrent neural networks, and transformer-based models, have shown remarkable potential in analyzing multimodal neuroimaging data.» [result]
  - structural/functional modality processing ← metadata.md (Abstract, Results) «These models can effectively process structural and functional imaging modalities, extracting relevant features and patterns associated with Alzheimer's pathology.» [result]
- **Dependencies**: none
- **Tags**: deep-learning, CNN, RNN, transformers, multimodal-neuroimaging

## C02: Multimodal neuroimaging integration improves diagnostic accuracy over single-modality approaches
- **Statement**: Integrating multiple imaging modalities is reported to improve diagnostic accuracy compared with single-modality approaches.
- **Status**: supported
- **Falsification criteria**: A review of the same evidence base showing that multimodal integration does not improve diagnostic accuracy relative to single-modality approaches.
- **Proof**: [E02, E03]
- **Evidence basis**: The abstract states this comparison directly but provides no effect size, modality pair, or dataset-level evidence.
- **Interpretation**: The claim should be read as an abstract-level synthesis result, not as a quantified benchmark.
- **Sources**:
  - multimodal accuracy improvement ← metadata.md (Abstract, Results) «Integration of multiple imaging modalities has demonstrated improved diagnostic accuracy compared to single-modality approaches.» [result]
- **Dependencies**: C01
- **Tags**: multimodal-integration, diagnostic-accuracy, single-modality-baseline

## C03: Deep learning shows promise for progression prediction and biomarker discovery
- **Statement**: Deep learning models are reported to show promise in predictive modeling, identifying potential biomarkers, and forecasting Alzheimer's disease progression.
- **Status**: supported
- **Falsification criteria**: A review of the same evidence base finding no support for predictive modeling, biomarker identification, or disease-progression forecasting using deep learning.
- **Proof**: [E02, E04]
- **Evidence basis**: The abstract's Results section states the predictive modeling, biomarker, and progression-forecasting roles directly.
- **Interpretation**: This is a forward-looking synthesis claim; no provided input specifies the biomarkers, prediction horizon, or validation outcomes.
- **Sources**:
  - predictive/biomarker/progression promise ← metadata.md (Abstract, Results) «Deep learning models have also shown promise in predictive modeling, identifying potential biomarkers and forecasting disease progression.» [result]
- **Dependencies**: C01
- **Tags**: predictive-modeling, biomarkers, disease-progression

## C04: Clinical translation remains limited by data, generalizability, interpretability, transparency, and ethics
- **Statement**: Deep-learning approaches for AD neurodiagnostics face significant hurdles from data heterogeneity, small sample sizes, limited generalizability across diverse populations, and the need to consider interpretability, transparency, and ethical implications.
- **Status**: supported
- **Falsification criteria**: Evidence that the reviewed literature has already resolved these data, generalizability, interpretability, transparency, and ethical barriers for clinical AD neurodiagnostics.
- **Proof**: [E04]
- **Evidence basis**: The abstract's Discussion section directly lists these challenges.
- **Interpretation**: This bounds the paper's positive claims and identifies the conditions under which future clinical deployment would need to be evaluated.
- **Sources**:
  - challenge list ← metadata.md (Abstract, Discussion) «Data heterogeneity, small sample sizes, and limited generalizability across diverse populations are significant hurdles.» [result]
  - translation considerations ← metadata.md (Abstract, Discussion) «The clinical translation of these models requires careful consideration of interpretability, transparency, and ethical implications.» [result]
- **Dependencies**: C01, C02, C03
- **Tags**: clinical-translation, heterogeneity, generalizability, interpretability, ethics
